Hims & Hers
Hims & Hers runs men's and women's telehealth brands treating sexual health, hair loss, weight, and mental health online.
Founded
2017Hims & Hers runs men's and women's telehealth brands treating sexual health, hair loss, weight, and mental health online.
hims.comCrawled Oct 16, 2026
The page offers ED treatment plans prescribed online by licensed providers, with discreet delivery.
Regrow hair with ingredients shown to achieve results. Personalized care, prescription treatment options, and discreet delivery.
Last longer with prescription treatment plans for premature ejaculation. Personalized care online, delivered discreetly.
The page discusses whether Viagra helps people last longer during sex and covers other premature ejaculation treatment options.
Hims answers questions about sex, hair, mental health, weight loss, and other topics.
A Hims study examines how smarter spending may support well-being during a recession.
According to a new Hims study, Americans are investing more in health and wellness — prioritizing what many now see as the ultimate luxury: a longer, better life.
The page reports on a study of the five love languages and which is most popular in the country.
Data reveals there are still many myths about men’s sexual health. Hint: Issues of sexual function are common to men of many ages.
Hims has a corporate team.
Hims & Hers is a multi-specialty telehealth platform available online at any time to patients across all 50 states, connecting them with licensed healthcare providers and evidence-based care.
Hims subscriptions offer access to partner care, advanced diagnostics, and preventive tools.
Expert‑led care, a private members‑only community, and exclusive savings from top health brands.
The page compares Hims and Eden for weight loss in 2025, including products, pricing, and subscription plans.
The page compares Hims and Found for weight loss in 2025, including products, pricing, and subscription models.
The page compares Hims and Mochi for weight loss, including products, pricing, and subscription models.
Here’s what to know about Hims vs. Noom for weight loss, including how they compare on products, pricing, and subscription models.
Dr. Claudia Berty, MBChB MRCGP DFSRH PGDipENT AFMCP is a (UK Board-Certified) General Practitioner, Member of the Royal College of General Practitioners and Medical Advisor for Hims & Hers.
Julia Switzer, MD, FACOG is a Board Certified Obstetrician Gynecologist and Medical Advisor for Hims & Hers.
Lynn Marie Morski, MD, JD, is a Mayo Clinic–trained physician and California-licensed attorney.
The company’s medical staff and network bring expertise to its platform.
Hims offers a more accessible, more personal approach to men’s healthcare—grounded in clinical excellence and designed for everyday life.
Hims says it is scaling its supply chain with a new peptide facility to support access to safe medicines for Americans nationwide.
The page describes the standards, team, and process behind a digital resource for men.
The Hims Weight Loss Membership provides eligible members access to GLP-1 medications and unlimited support from a dedicated Care Team.
The page describes online men's healthcare services, including weight loss care, ED treatment, lab testing, and testosterone support.
Hims & Hers Health shares fall 8.06% to $23.03 after the telehealth company announces a planned private placement of $300 million in convertible senior notes due 2032. The offering is intended for qualified institutional buyers, and the stock declines $2.02 on Monday.
May 2026 · RTTNewsNews article
Hims plans to offer up to $300 million in convertible notes to support its expansion priorities. The funds are intended for international expansion, Eucalyptus, and technology investment.
May 2026 · GuruFocusNews article
Hims & Hers announces a $1.15 billion acquisition of Australian telehealth company Eucalyptus. The company says the acquisition will add $450 million in annualized revenue.
Feb 2026 · The Motley FoolNews article
Hims & Hers Health shares slide 10% in after-hours trading Monday after the telehealth company reports second-quarter revenue below Wall Street estimates. The company also issues cautious guidance amid legal and regulatory scrutiny over its compounded weight-loss drug offerings.
Aug 2025 · Investing.comNews article